Long-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent
| Autor: | Laura Mauri, David E. Kandzari, David F. Kong, Kevin J. Anstrom, Endeavor Iii Investigators, Rex Edwards, Martin B. Leon, Patricia A. Cowper, Eric L. Eisenstein |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Stent medicine.disease Surgery law.invention Clinical trial Randomized controlled trial Drug-eluting stent law Internal medicine Angioplasty Coronary stent medicine Cardiology Myocardial infarction business Cardiology and Cardiovascular Medicine Case report form |
| Zdroj: | JACC: Cardiovascular Interventions. 2(12):1199-1207 |
| ISSN: | 1936-8798 |
| DOI: | 10.1016/j.jcin.2009.10.009 |
| Popis: | Objectives The aim of this study was to evaluate clinical and economic outcomes for subjects receiving zotarolimus-eluting (ZES) (n = 323) versus sirolimus-eluting stents (SES) (n = 113) in the ENDEAVOR III (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) clinical trial. Background Although previous clinical trials have evaluated long-term clinical outcome for drug-eluting stents, none considered their economic implications. Methods We analyzed case report form information with quality-of-life adjustment and Medicare cost weights applied from secondary sources; compared differences in clinical outcomes, quality-adjusted survival, medical resource use, and medical costs; and evaluated cost-effectiveness through 3-year follow-up. Results The use of ZES versus SES reduced the 3-year rates/100 subjects of death or myocardial infarction (3.9 vs. 10.8; difference, −6.9; 95% confidence interval [CI]: −13.0 to 0.8; p = 0.028), with no difference in target vessel revascularization rates (17.9 vs. 12.2; difference, 5.7; 95% CI: −3.7 to 15.1; p = 0.23) but greater use of coronary artery bypass graft (CABG) surgery (3.5 vs. 0.0; difference 3.5; 95% CI: 1.3 to 5.7; p = 0.002). After discounting at 3% per annum, total medical costs for ZES versus SES were similar ($23,353 vs. $21,657; difference, $1,696; 95% CI: −$1,089 to $4,482, p = 0.23), and the 3-year cost-effectiveness ratio was $57,002/quality-adjusted life year. Conclusions Despite a reduction in death or myocardial infarction and no difference in total revascularizations, medical costs were not decreased due to increased CABG repeat revascularization procedures for subjects receiving ZES versus SES. If future trials observe similar differences, improved safety with no difference in medical costs, the use of ZES versus SES will be a clinically and economically attractive treatment strategy. (The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial [ENDEAVOR III]; NCT00217256) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|